BETHLEHEM, Pa.--(BUSINESS WIRE)--Saladax Biomedical, Inc. today announced that Myriad Genetics, Inc. (NASDAQ:MYGN) has developed and launched its seventh molecular diagnostic product, OnDoseTM. OnDose™, which utilizes patent rights licensed from Saladax. OnDose provides a quantitative measure in blood of exposure of the patient to 5-Fluorouracil (5-FU), providing oncologists with a routinely available tool for personalizing infusion chemotherapy drug dosing to help optimize clinical efficacy and reduce toxic side effects.
